PLoS Computational Biology
September 1, 2025
Jordy Peeters, Dimitri de Bundel, Kenno Vanommeslaeghe
The serotonin-2A receptor (5-HT2AR) is an interesting target for drug design in the context of antidepressants that might have a rapid onset of action and/or be effective in treatment-resistant cases. The main challenge, however, is that the activation of this receptor can provoke hallucinations. Recent studies have shown that activating the receptor with certain (partial) agonists could...
The Journal of Clinical Psychiatry
September 1, 2025
Vania Modesto-Lowe, Deanna Sgambato, Pa-C Margaret Chaplin
To the Editor: Psychedelic-assisted therapy (PAT) combines psychedelics, such as psilocybin, with guided psychotherapeutic support. 1 These substances interact with patient's mindset ("set") and the surrounding environment ("setting"), 2 making the context of the experience a critical factor in therapeutic outcomes.As these substances gain recognition for their therapeutic potential, it is...
Cureus
September 1, 2025
Aditya Lal Vallath, Ratan P Yadav, Michelle Bass et al.
Nitrous oxide (N₂O), a dissociative anesthetic and analgesic, has seen a concerning rise in recreational abuse, particularly among adolescents and young adults. This resurgence is fueled by its easy accessibility in large-volume, flavored canisters marketed as cooking aids, which exploit legal loopholes, as well as its promotion through popular culture and social media platforms like TikTok and...
Human Psychopharmacology: Clinical and Experimental
September 1, 2025
Renée Martin-Willett, Carillon J. Skrzynski, Angela D Bryan et al.
This study examined the effects of tetrahydrocannabinol (THC) and cannabidiol (CBD) on negative mood and drinking behaviors, and whether those effects were moderated by levels of perceived discrimination among participants who identify with a racial, ethnic, gender, or sexual identity that is underrepresented in research. Participants were either not using cannabis, using cannabis with THC, or...
Philosophy, Psychiatry, & Psychology
September 1, 2025
David Zheng
abstract: Paul's concepts of "Transformative Experiences" (TE) has sparked extensive discussion on multiple epistemological and ethical issues within philosophy. In particular, Paul's work has inspired significant work on the possibility of informed consent with regard to medical interventions that may induce said TEs. One such intervention, namely Psychedelic-assisted Therapy (PAT), has been...
Drug Science, Policy and Law
September 1, 2025
David Nutt, David Erritzøe, Anne Katrin Schlag et al.
9 citations
Psychedelics are undergoing a clinical research renaissance, with compounds such as psilocybin advancing to Phase 3 trials for treatment-resistant depression and receiving fast-track or breakthrough designations from regulatory agencies. Despite this progress, the field lacks standardized terminology to guide clinical development, dosing, safety monitoring, and regulatory classification. Here,...
International Journal of Innovative Technologies in Social Science
September 1, 2025
Anna Blazhkova, Magdalena Czaja, Hanna Sitka et al.
Introduction: Recently, there has been a significant increase in interest in the use of psychedelics for various psychiatric conditions. Psilocybin is receiving particular attention as a psychoactive substance with significant therapeutic potential. Recent research focuses on its possible benefits in the treatment of major depressive disorders (MDD) and anorexia nervosa (AN). Purpose of the...
Physiology & Behavior
September 1, 2025
Yiru Dong, Sebastian Goodwin-Groen, Jessie Ma et al.
4 citations
The activity-based anorexia (ABA) animal model captures key maladaptive behaviors of anorexia nervosa - starvation-evoked hyperactivity, voluntary food restriction, severe weight loss and elevated anxiety-like behavior. By repeating ABA induction, the model reveals an animal's gain of resilience against ABA relapses and concomitant synaptic plasticity. We review findings on the efficacy of...
August 29, 2025
David A. Gorelick
The prevalence of cannabis-induced psychosis has increased substantially, possibly due to higher cannabis potency and greater use. Antipsychotic medication reduced hospitalization risk by 25% for psychosis, 25% for substance use disorders, and 50% for medical conditions. For psychosis-related hospitalization, long-acting injectable aripiprazole or olanzapine reduced risk by 75%—twice as...
August 29, 2025
Romesha Uduwawela
<p><strong>Psilocybin, the psychoactive compound found in certain mushrooms, has gained increasing attention for its potential therapeutic applications in mental health treatment. While clinical research highlights its efficacy in alleviating mental disorders, such as depression, anxiety, PTSD, and substance use disorders, much remains to be known about the role of acute doses of psilocybin...